STOCK ISSUANCE AGREEMENTStock Issuance Agreement • June 11th, 2012 • Oragenics Inc • Pharmaceutical preparations • Delaware
THIS STOCK ISSUANCE AGREEMENT (“Agreement”) is made and entered into as of June 5, 2012 (the “Effective Date”), by and among Oragenics, Inc., a Florida corporation (the “Company”) and Intrexon Corporation, a Virginia corporation (“Intrexon”).
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTChannel Collaboration Agreement • June 11th, 2012 • Oragenics Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of June 5, 2012 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 3000 Bayport Drive, Suite 685, Tampa, FL 33607 (“Oragenics”). Intrexon and Oragenics may be referred to herein individually as a “Party”, and collectively as the “Parties.”
FIRST AMENDMENT TO SECURITY AGREEMENTSecurity Agreement • June 11th, 2012 • Oragenics Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO SECURITY AGREEMENT (this “First Amendment”) is entered into as of June 5, 2012, by and between ORAGENICS, INC., a Florida corporation located at 3000 Bayport Drive, Suite 685 Tampa, Florida 33607 (the “Company” or “Borrower”), and KOSKI FAMILY LIMITED PARTNERSHIP, a Texas limited partnership having a mailing address of 3525 Turtle Creek Boulevard, Unit 19-B, Dallas, Texas 75219 (“KFLP” or “Lender”).
